On Wednesday (April 18) the most recent Canadian cannabis licensed producer (LP) to join the country’s premier public stock exchange announced a venture to develop medical marijuana products for pets.

CannTrust Holdings (TSX:TRST) unveiled a deal in paper with Grey Wolf Animal Health, a private healthcare company working on a portfolio of products for pets.


“We look forward to launching, together with Grey Wolf, industry leading, high quality, standardized cannabis products specifically designed for pets,” Eric Paul, CEO of CannTrust said in the statement.

The proposal is for this partnership to create a new subsidiary of Grey Wolf, which will develop new products combining the two company’s expertise. Additionally, CannTrust will “become a substantial shareholder in Grey Wolf.”

The companies failed to offer more details on what kind of products they envision developing or what kind of ailments will be treated with these cannabis goods.

Cases with animals being given marijuana by their owners have provided mixed returns in the past. While some pet owners have successfully treated their mascots with cannabis products, for others it has put the animals in harm’s way.

Earlier this year in Calgary, the CBC reported an increase of sick dogs made by cannabis. CARE Centre Animal Hospital medical director Danny Joffe told CBC there is a concern for future once cannabis becomes legal in Canada.

The co-founder and CEO of Grey Wolf, Dr. Ian Sandler said CannTrust was the “ideal partner” for his company.

Analyst sentiment on recent TSX graduate

Experts in the industry have been bullish on CannTrust Holdings since the company upgraded to the Toronto Stock Exchange (TSX).

On the market research and price target prediction aggregator site TipRanks, CannTrust currently holds a “Moderate Buy” rating based on three analysts recommendations. The average price target for the company’s stock sits at C$17.25.

For his most recent research note on CannTrust, GMP Securities analyst Martin Landry decreased his price target on the company to C$16, while still keeping his “Buy” rating.

The main cause of concern for Landry was the company’s low returns during its fourth quarter. In his note Landry wrote:

The main disappointment came from production costs per gram, which increased significantly as some grow rooms in the Vaughan facility were dedicated to providing the Niagara facility with seedlings instead of producing sellable products. In addition, the company purchased third party products to bridge the demand gap as the Vaughan facility was capacity constrained, creating a $1.8m headwind.

However, he noted all of these issues could dissipate since CannTrust’s Niagara facility obtained a sales license from Health Canada. Landry also indicated the next catalyst for the company he’s tracking is a gel caps sales license.

“Management expects approval in the coming weeks which could re-accelerate patient acquisition, revenues and drive gross margin expansion as capsules typically enjoy higher prices,” Landry wrote.

Another recent research note on the company was issued by Echelon Wealth Partners analyst Russell Stanley in April, following a venture deal from the company with Stenocare, also maintained a “Speculative Buy” rating and a 12-month stock price target of C$18.50.

As part of the Investing News Network’s (INN) quarterly update on the cannabis industry, Greg Taylor, portfolio manager with Redwood Asset Management, said he was surprised CannTrust’s upgrade didn’t cause a bigger splash for the company.

“Once … the TRST was uplisted to the TSX–which I thought would be a major positive and the stock would see a re-rating higher, but it didn’t seem to be noticed by the market,” Taylor said.

Investor takeaway

Since its launch on the TSX on March 5, the company’s share price has decreased 28.44 percent in value. After markets closed on Wednesday TRST took a 0.93 percent drop in day trading and is valued at C$6.40 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less